IDXX Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of 23.87% compared to IDEXX Laboratories's net margin of 11.12%. IDEXX Laboratories's return on equity of 57.37% beat Boston Scientific's return on equity of 8.91%.

IDEXX Laboratories has a consensus price target of $478.62, signalling upside risk potential of 14.49%. On the other hand Boston Scientific has an analysts' consensus of $100.72 which suggests that it could grow by 6.15%. Given that IDEXX Laboratories has higher upside potential than Boston Scientific, analysts believe IDEXX Laboratories is more attractive than Boston Scientific.

IDEXX Laboratories has a beta of 1.364, which suggesting that the stock is 36.364% more volatile than S&P 500. In comparison Boston Scientific has a beta of 0.800, suggesting its less volatile than the S&P 500 by 20.007%.

IDEXX Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDEXX Laboratories pays -- of its earnings as a dividend. Boston Scientific pays out 1.76% of its earnings as a dividend. Boston Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

IDEXX Laboratories quarterly revenues are $975.5M, which are smaller than Boston Scientific quarterly revenues of $4.2B. IDEXX Laboratories's net income of $232.8M is lower than Boston Scientific's net income of $468M. Notably, IDEXX Laboratories's price-to-earnings ratio is 40.31x while Boston Scientific's PE ratio is 78.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEXX Laboratories is 9.09x versus 8.84x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of 23.87% compared to IDEXX Laboratories's net margin of 14.25%. IDEXX Laboratories's return on equity of 57.37% beat Insulet's return on equity of 49.55%.

IDEXX Laboratories has a consensus price target of $478.62, signalling upside risk potential of 14.49%. On the other hand Insulet has an analysts' consensus of $292.08 which suggests that it could grow by 7.45%. Given that IDEXX Laboratories has higher upside potential than Insulet, analysts believe IDEXX Laboratories is more attractive than Insulet.

IDEXX Laboratories has a beta of 1.364, which suggesting that the stock is 36.364% more volatile than S&P 500. In comparison Insulet has a beta of 1.218, suggesting its more volatile than the S&P 500 by 21.787%.

IDEXX Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDEXX Laboratories pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

IDEXX Laboratories quarterly revenues are $975.5M, which are larger than Insulet quarterly revenues of $543.9M. IDEXX Laboratories's net income of $232.8M is higher than Insulet's net income of $77.5M. Notably, IDEXX Laboratories's price-to-earnings ratio is 40.31x while Insulet's PE ratio is 46.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEXX Laboratories is 9.09x versus 10.47x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 23.87% compared to IDEXX Laboratories's net margin of 36.03%. IDEXX Laboratories's return on equity of 57.37% beat Regeneron Pharmaceuticals's return on equity of 17.19%.

IDEXX Laboratories has a consensus price target of $478.62, signalling upside risk potential of 14.49%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $1,036.70 which suggests that it could grow by 48.76%. Given that Regeneron Pharmaceuticals has higher upside potential than IDEXX Laboratories, analysts believe Regeneron Pharmaceuticals is more attractive than IDEXX Laboratories.

IDEXX Laboratories has a beta of 1.364, which suggesting that the stock is 36.364% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.098, suggesting its less volatile than the S&P 500 by 90.217%.

IDEXX Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDEXX Laboratories pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

IDEXX Laboratories quarterly revenues are $975.5M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.7B. IDEXX Laboratories's net income of $232.8M is lower than Regeneron Pharmaceuticals's net income of $1.3B. Notably, IDEXX Laboratories's price-to-earnings ratio is 40.31x while Regeneron Pharmaceuticals's PE ratio is 17.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEXX Laboratories is 9.09x versus 5.79x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Zoetis has a net margin of 23.87% compared to IDEXX Laboratories's net margin of 28.56%. IDEXX Laboratories's return on equity of 57.37% beat Zoetis's return on equity of 48%.

IDEXX Laboratories has a consensus price target of $478.62, signalling upside risk potential of 14.49%. On the other hand Zoetis has an analysts' consensus of $211.25 which suggests that it could grow by 29.35%. Given that Zoetis has higher upside potential than IDEXX Laboratories, analysts believe Zoetis is more attractive than IDEXX Laboratories.

IDEXX Laboratories has a beta of 1.364, which suggesting that the stock is 36.364% more volatile than S&P 500. In comparison Zoetis has a beta of 0.891, suggesting its less volatile than the S&P 500 by 10.852%.

IDEXX Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zoetis offers a yield of 1.06% to investors and pays a quarterly dividend of $0.43 per share. IDEXX Laboratories pays -- of its earnings as a dividend. Zoetis pays out 29.52% of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

IDEXX Laboratories quarterly revenues are $975.5M, which are smaller than Zoetis quarterly revenues of $2.4B. IDEXX Laboratories's net income of $232.8M is lower than Zoetis's net income of $682M. Notably, IDEXX Laboratories's price-to-earnings ratio is 40.31x while Zoetis's PE ratio is 30.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEXX Laboratories is 9.09x versus 8.16x for Zoetis. Usually stocks with elevated PS ratios are considered overvalued.